Human Papilloma Virus Vaccine for Cervical Cancer Now Covered

The Human Papilloma Virus (HPV) is a concern for girls and young women because it can lead to cervical cancer. The HPV vaccine was developed to prevent cervical cancer infection and has been a TRICARE covered benefit since October 1, 2006.

The Centers for Disease Control and Prevention (CDC) reported that in 2006, approximately 9,700 cases of cervical cancer were diagnosed in the United States, and approximately 3,700 women died from the disease. Nearly all cervical cancer cases are associated with an HPV infection.

The recommended age for initial administration is 11-12, or age range of 13-26, if not previously administered. The CDC has determined that it can be safely administered for girls as early as age 9. The CDC recommends a three-dose schedule for the HPV vaccine with the second and third doses administered two and six months after the first dose. After the age of 26, no efficacy has been established; therefore, it will not be a covered benefit.